The 4 analysts offering 12-month price forecasts for Zynerba Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 11.00 and a low estimate of 1.00. The median estimate represents a +689.53% increase from the last price of 0.89.
The current consensus among 5 polled investment analysts is to Buy stock in Zynerba Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.23
Reporting Date Nov 14
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.